EA201291314A1 - Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности - Google Patents
Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточностиInfo
- Publication number
- EA201291314A1 EA201291314A1 EA201291314A EA201291314A EA201291314A1 EA 201291314 A1 EA201291314 A1 EA 201291314A1 EA 201291314 A EA201291314 A EA 201291314A EA 201291314 A EA201291314 A EA 201291314A EA 201291314 A1 EA201291314 A1 EA 201291314A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- chemokine
- compositions
- kidney damage
- methods
- damage
- Prior art date
Links
- 210000003734 kidney Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 201000006370 kidney failure Diseases 0.000 title 1
- 102000019034 Chemokines Human genes 0.000 abstract 4
- 108010012236 Chemokines Proteins 0.000 abstract 4
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 abstract 1
- 102000003908 Cathepsin D Human genes 0.000 abstract 1
- 108090000258 Cathepsin D Proteins 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000014429 Insulin-like growth factor Human genes 0.000 abstract 1
- 102000003815 Interleukin-11 Human genes 0.000 abstract 1
- 108090000177 Interleukin-11 Proteins 0.000 abstract 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 108010008707 Mucin-1 Proteins 0.000 abstract 1
- 102000007298 Mucin-1 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000056189 Neutrophil collagenases Human genes 0.000 abstract 1
- 108030001564 Neutrophil collagenases Proteins 0.000 abstract 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 abstract 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000104 diagnostic biomarker Substances 0.000 abstract 1
- 229940074383 interleukin-11 Drugs 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 239000000092 prognostic biomarker Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4745—Insulin-like growth factor binding protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5431—IL-11
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35796510P | 2010-06-23 | 2010-06-23 | |
| US35795610P | 2010-06-23 | 2010-06-23 | |
| US36430010P | 2010-07-14 | 2010-07-14 | |
| US36430410P | 2010-07-14 | 2010-07-14 | |
| PCT/US2011/001127 WO2011162820A1 (en) | 2010-06-23 | 2011-06-23 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201291314A1 true EA201291314A1 (ru) | 2013-11-29 |
Family
ID=45371738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201291314A EA201291314A1 (ru) | 2010-06-23 | 2011-06-23 | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130165344A1 (https=) |
| EP (3) | EP2899545B1 (https=) |
| JP (2) | JP2013531240A (https=) |
| CN (2) | CN103080743B (https=) |
| AU (1) | AU2011269774B2 (https=) |
| CA (1) | CA2803500A1 (https=) |
| EA (1) | EA201291314A1 (https=) |
| HK (1) | HK1212770A1 (https=) |
| MX (1) | MX2013000220A (https=) |
| NZ (1) | NZ606124A (https=) |
| WO (1) | WO2011162820A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2013184868A1 (en) | 2012-06-06 | 2013-12-12 | The Cleveland Clinic Foundation | Prediction of acute kidney injury from a post-surgical metabolic blood panel |
| ES2792227T3 (es) | 2014-09-26 | 2020-11-10 | Somalogic Inc | Predicción de evento de riesgo cardiovascular y usos de la misma |
| CA2965153C (en) | 2014-10-20 | 2023-10-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2016083374A1 (en) | 2014-11-25 | 2016-06-02 | F. Hoffmann-La Roche Ag | Biomarkers of fast progression of chronic kidney disease |
| CN107735147A (zh) * | 2015-05-12 | 2018-02-23 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| EP4063853A1 (en) | 2017-01-12 | 2022-09-28 | Astute Medical, Inc. | Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement |
| GB201703313D0 (en) * | 2017-03-01 | 2017-04-12 | Mologic Ltd | Urinary tract infection diagnostic |
| CA3176021A1 (en) | 2018-12-28 | 2020-07-02 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| WO2021216505A1 (en) * | 2020-04-21 | 2021-10-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cxcl13 gene |
| CN113552369B (zh) * | 2021-07-23 | 2023-10-20 | 江苏省中医院 | 蛋白标志物联合用于2型糖尿病、2型糖尿病肾病的诊断的用途 |
| KR20250068980A (ko) * | 2023-11-10 | 2025-05-19 | 계명대학교 산학협력단 | 당뇨병성 신경병증 조기 진단용 바이오마커 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| AU1772992A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| JP3290988B2 (ja) | 1991-04-11 | 2002-06-10 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | 多重リガンドを同時検出する新規接合体及び検定法 |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US6218122B1 (en) * | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
| CN1374525A (zh) * | 2001-12-31 | 2002-10-16 | 陕西超英生物医学研究开发有限公司 | 一种抗体芯片、其制备技术及其检测方法 |
| CN1871517A (zh) * | 2002-02-19 | 2006-11-29 | 免疫公司 | 快速有效分离循环癌细胞的方法和试剂 |
| MXPA05010385A (es) * | 2003-03-27 | 2006-03-08 | Childrens Hosp Medical Center | Metodo y estuche para detectar el inicio temprano de lesion celular tubular renal. |
| WO2006044779A1 (en) * | 2004-10-14 | 2006-04-27 | Northwestern University | Detection and treatment of renal cancer |
| EP2604703B1 (en) * | 2005-03-14 | 2017-02-01 | The Board of Trustees of the Leland Stanford Junior University | Methods for evaluating graft survival in a solid organ transplant recipient |
| CN101358976A (zh) * | 2008-04-28 | 2009-02-04 | 北京华大吉比爱生物技术有限公司 | 检测六项肿瘤标志物的微阵列-酶联免疫检测试剂盒 |
| EP2913676A1 (en) * | 2008-11-10 | 2015-09-02 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2009316387B2 (en) * | 2008-11-22 | 2015-01-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN101735317A (zh) * | 2008-11-25 | 2010-06-16 | 中国科学院北京基因组研究所 | Cathepsin D抗原多肽、应用及含有该多肽的检测试剂盒 |
| US20120315649A1 (en) * | 2009-08-28 | 2012-12-13 | Astute Medical ,Inc. a corporation | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2011075744A1 (en) * | 2009-12-20 | 2011-06-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN102539745B (zh) * | 2010-12-31 | 2013-03-06 | 中国人民解放军第三〇九医院 | 移植肾排斥反应早期诊断及预警试剂盒 |
| KR101325928B1 (ko) * | 2013-01-14 | 2013-11-07 | 이명재 | 설치가 간편한 논 물꼬용 패널 |
-
2011
- 2011-06-23 NZ NZ606124A patent/NZ606124A/en not_active IP Right Cessation
- 2011-06-23 US US13/806,759 patent/US20130165344A1/en not_active Abandoned
- 2011-06-23 EA EA201291314A patent/EA201291314A1/ru unknown
- 2011-06-23 EP EP15151607.7A patent/EP2899545B1/en not_active Not-in-force
- 2011-06-23 CN CN201180038804.5A patent/CN103080743B/zh not_active Expired - Fee Related
- 2011-06-23 MX MX2013000220A patent/MX2013000220A/es not_active Application Discontinuation
- 2011-06-23 WO PCT/US2011/001127 patent/WO2011162820A1/en not_active Ceased
- 2011-06-23 EP EP18189709.1A patent/EP3489688A1/en not_active Withdrawn
- 2011-06-23 EP EP11798515.0A patent/EP2585826A4/en not_active Withdrawn
- 2011-06-23 CA CA2803500A patent/CA2803500A1/en not_active Abandoned
- 2011-06-23 JP JP2013516566A patent/JP2013531240A/ja active Pending
- 2011-06-23 CN CN201510428093.2A patent/CN105137085A/zh active Pending
- 2011-06-23 AU AU2011269774A patent/AU2011269774B2/en not_active Ceased
-
2016
- 2016-01-20 HK HK16100597.9A patent/HK1212770A1/zh unknown
- 2016-03-02 JP JP2016040339A patent/JP2016136154A/ja active Pending
-
2017
- 2017-05-24 US US15/604,573 patent/US20170254816A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3489688A1 (en) | 2019-05-29 |
| HK1179344A1 (en) | 2013-09-27 |
| CN103080743A (zh) | 2013-05-01 |
| US20130165344A1 (en) | 2013-06-27 |
| MX2013000220A (es) | 2013-03-22 |
| EP2899545B1 (en) | 2018-08-22 |
| JP2013531240A (ja) | 2013-08-01 |
| NZ606124A (en) | 2015-05-29 |
| CN103080743B (zh) | 2015-07-22 |
| EP2899545A1 (en) | 2015-07-29 |
| CA2803500A1 (en) | 2011-12-29 |
| WO2011162820A1 (en) | 2011-12-29 |
| CN105137085A (zh) | 2015-12-09 |
| EP2585826A1 (en) | 2013-05-01 |
| JP2016136154A (ja) | 2016-07-28 |
| AU2011269774A1 (en) | 2013-02-07 |
| AU2011269774B2 (en) | 2015-07-30 |
| US20170254816A1 (en) | 2017-09-07 |
| HK1212770A1 (zh) | 2016-06-17 |
| EP2585826A4 (en) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201291314A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EA201290629A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EA201490384A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EA201290711A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| NZ599105A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| EA201290387A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| ES2506116T3 (es) | Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo | |
| EA201100231A1 (ru) | Диагностический анализ на основе антител | |
| EA201290192A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EP2813848A3 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| EP2585827A4 (en) | METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency | |
| EP2811036A3 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| EP2767833A3 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| EA201290056A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EA201490105A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| WO2007117444A3 (en) | Protein detection by aptamers | |
| WO2008067065A3 (en) | Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers | |
| JP2013539032A5 (https=) | ||
| NZ607703A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2008060607A3 (en) | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome | |
| WO2008061149A3 (en) | Methods and compositions for diagnosis and prognosis of renal artery stenosis | |
| MX2011008323A (es) | Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal. | |
| MY162697A (en) | Methods, devices and kits for detecting or monitoring acute kidney injury | |
| BR112013021056A2 (pt) | anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical | |
| RU2013118647A (ru) | Способы диагностики болезни лайма |